

Receipt date: 12/18/2007

10551847 - GAU: 1648

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10551847
Filing Date	2006-06-23
First Named Inventor	HAIXIANG, LIN
Art Unit	1648
Examiner Name	LE, EMILY M
Attorney Docket Number	NBMP-001(SP)

9	4185089		1980-01-22	Derrien, M., et al.	
10	4186194		1980-01-29	Adam, A., et al.	
11	4235771		1980-11-25	Adam, A., et al.	
12	4314998		1982-02-09	Yamamura, Y., et al.	
13	4323559		1982-04-06	Audibert, F., et al.	
14	4327085		1982-04-27	Audibert, F., et al.	
15	4369178		1983-01-18	Yamamura, Y., et al.	
16	6008200		1999-28-12	Krieg, A., et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20070166800	A1	2007-07-19	Lin HAIXIANG, L.	

2/17/10

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Receipt date: 12/18/2007		Application Number		10551847	10551847 - GAU: 1648
			Filing Date		2006-06-23	
			First Named Inventor		HAIXIANG, LIN	
			Art Unit		1648	
			Examiner Name		LE, EMILY M	
			Attorney Docket Number		NBMP-001(SP)	

	2	20070166239	A1	2007-07-19	Lin HAIXIANG, L.	
--	---	-------------	----	------------	--------------------------------	--

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	JP01093540	JP	A2	1989-04-12	Mount Sinai Hospital Corp		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	ELLOUZ, F., et al. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochemical and Biophysical Research Communications. 1974, vol. 59, no. 4, pp. 1317-1325.	<input type="checkbox"/>
	2	GUPTA, R. K., et al. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine. 1995, vol. 13, no. 14, pp. 1263-1278.	<input type="checkbox"/>
	3	GUPTA, R. K., et al. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine. 1993, vol. 11, pp. 293-306.	<input type="checkbox"/>
	4	KANZLER, H., et al. Therapeutic targeting of innate immunity with toll-like receptor agonists and antagonists. Nature Medicine. 2007, vol. 13, no. 5, pp 552-559. E-pub 3 May 2007.	<input type="checkbox"/>
	5	KENNEY, R. T., et al. Meeting report, 2nd meeting on novel adjuvants currently in/close to human clinical testing, World Health Organization - Organization Mondiale de la Sante, Fondation Merieux, Annecy, France, 5-7 June 2000. Vaccine. 2002, vol. 20, pp. 2155-2163.	<input type="checkbox"/>